Lilly Wins Second Accelerated Approval for Reversible BTK Inhibitor

[cafead]

via The FDA on Friday granted accelerated approval to Eli Lilly’s reversible BTK inhibitor Jaypirca (pirtobrutinib) for the treatment of chronic lymphocytic leukemia or small lymphocytic leukemia in adult patients who have undergone at least two prior lines of therapy, including another BTK inhibitor and a BCL-2 inhibitor.

article source